Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News

Press

MindBio Adopts New Equity Incentive Plan

Vancouver, British Columbia – TheNewswire – April 2, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company pioneering new treatments for mental health conditions announces that it has adopted a new equity incentive plan (the “New Plan”). The New Plan is a 20% rolling equity incentive plan that provides for the issuance…

Revive Therapeautics Press

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it…

Clearmind Press

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment

Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the launch of its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial of its MEAI-based…

Psyence Press

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

New York, New York–(Newsfile Corp. – March 31, 2025) – Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) releases the following update: Dear Shareholders and Future Investors: At Psyence BioMed, we are truly grateful for the ongoing support and trust of our shareholders. Your dedication to our vision drives our growth, and we’re…

Filament Health Press

Filament Health Reports Q4 and Year End 2024 Financial Results and Operational Highlights

VANCOUVER, BC, April 1, 2025 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2024. “Over the course of 2024, we continued to expand Filament’s position as a leading global supplier of…

Press Release Press

Neural Therapeutics Commences Trading on Frankfurt Stock Exchange

Toronto, Ontario–(Newsfile Corp. – March 31, 2025) – Neural Therapeutics Inc. (CSE: NURL) (FSE: M6B) (“Neural“or the “Company“), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, is pleased to announce that shares of the company have commenced trading on the Frankfurt Stock Exchange under ticker…

Press Release Press

MindBio Acquires Life AI Corp. Pty. Ltd.

Vancouver, British Columbia – TheNewswire – March 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing, is pleased to announce the completion of its acquisition of all of the outstanding share capital of Life AI Corp. Pty. Ltd. (“Life AI”) pursuant to a definitive share purchase agreement…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.